PolyPeptide follows an integrated approach for the management of environmental, social and governance (ESG) topics
that are considered material for its business. As a contract development and manufacturing organization (CDMO)
serving pharma and biotech customers, PolyPeptide must adhere to stringent product quality requirements and
regulations to protect the safety of patients. The Group seeks to promote corporate responsibility and to follow
fundamental principles of business ethics and compliance.
For further information regarding PolyPeptide’s approach on Corporate Responsibility please refer to our Corporate Responsibility Report as part of the Annual Report 2023.
This Corporate Responsibility Report has been prepared in accordance with art. 964b of the Swiss Code of Obligations (CO) concerning transparency on non-financial matters and presents PolyPeptide’s first report with reference to the GRI Standards.
For information regarding our sustainability efforts at our Swedish site, please refer to:
- 2021 Sustainability Report (prepared in compliance with Swedish law)
- 2022 Sustainability Report (prepared in compliance with Swedish law)